Maximizing PK and ADA Evaluation Efficiency Using Cutting-Edge Rabbit Antibody Development Technology: An Upcoming Webinar Hosted by Xtalks
In this free webinar, learn about the relevance of anti-idiotypic antibodies (anti-ID Abs) in antibody development. Attendees will learn why rabbits are the preferred host for generating high-performance anti-ID Abs. The featured speaker will discuss the discovery strategies and capabilities for developing rabbit anti-ID Abs.
TORONTO, Sept. 30, 2024 /PRNewswire-PRWeb/ -- Rabbits possess a robust and unique immune system that generates antibodies with superior specificity, affinity, and diversity compared to rodents. This makes them highly recommended for producing high-quality antibodies. In the dynamic field of pharmaceutical development, the need for high precision and rigorous safety validation is critical to ensuring the efficacy and safety of new therapeutics.
Therefore, anti-idiotypic antibodies (anti-ID Abs) play a crucial role in this process by binding to therapeutic drugs in biological fluids, facilitating drug validation and safety evaluation. They are commonly used in pharmacokinetics (PK) and pharmacodynamics (PD) assays to assess drug efficacy and are instrumental in evaluating drug safety through anti-drug antibody (ADA) assays, which measure immunogenicity.
In this webinar, the expert speaker will provide a detailed overview of anti-ID Abs, exploring their significance and applications. She will also delve into the reasons why rabbits are the preferred host for generating high-performance anti-ID Abs and highlight the advantages that make them ideal for this purpose. Additionally, attendees will gain insights into the advanced techniques and methodologies to optimize the development of these crucial antibodies, enhancing therapeutic and diagnostic outcomes in the biopharmaceutical industry.
Register now to discover the advantages of rabbit anti-ID Abs and learn how to optimize antibody development for enhanced PK and ADA evaluation efficiency.
Join Dr. Hui Foon Tan, PhD, Sr. Global Product Manager - Antibody, GenScript Biotech, for the live webinar on Friday, October 18, 2024, at 10am EDT (4pm CEST/EU-Central).
For more information, or to register for this event, visit Maximizing PK and ADA Evaluation Efficiency Using Cutting-Edge Rabbit Antibody Development Technology.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com, https://xtalks.com
View original content to download multimedia:https://www.prweb.com/releases/maximizing-pk-and-ada-evaluation-efficiency-using-cutting-edge-rabbit-antibody-development-technology-an-upcoming-webinar-hosted-by-xtalks-302262150.html
SOURCE Xtalks
Upcoming Life Sciences Events
- November 2024
- Philadelphia: Advanced Therapies USA
- London: Inv€$tival Showcase
- EABR Nanoparticles Platform for Hybrid mRNA Vaccine
Latest company news
MediPharm Labs Sets Date to Report Third Quarter 2024 Financial Results